盈利预期和评级 - Compass Therapeutics, Inc.最近被升级为Zacks Rank 2 (Buy)，这是因为其盈利预期呈上升趋势[1] - Zacks评级系统主要依赖于公司盈利前景的变化，通过跟踪卖方分析师对当前和未来年度的EPS预测来进行评级[2] - Compass Therapeutics, Inc.的盈利预期上升和评级升级基本上意味着公司基础业务的改善，投资者对这一改善的业务趋势的认可应推动股价上涨[6] 盈利预期修订 - Compass Therapeutics, Inc.的盈利预期修订表明公司预计在2023年12月的财政年度将每股亏损0.33美元，同比增长10.8%[9] - 过去三个月，分析师们一直在稳步提高对Compass Therapeutics, Inc.的盈利预期，公司的Zacks Consensus Estimate增长了2.3%[10] Zacks评级系统 - 机构投资者使用盈利和盈利预测来计算公司股票的公允价值，盈利预测的增加或减少会直接影响股票的公允价值，从而引发股价的波动[5] - Zacks评级系统有效利用盈利预测修订的力量，因此跟踪这些修订以做出投资决策可能会带来实质性回报[7] - Zacks评级系统保持了对超过4000只股票的'买入'和'卖出'评级的平等比例，只有Zacks覆盖的股票中的前5%获得'Strong Buy'评级，接下来的15%获得'Buy'评级，因此公司被列入Zacks覆盖的股票前20%意味着其具有优秀的盈利预期修订特性，有望在短期内产生超越市场的回报[11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delawa ...

公司产品 - Compass Therapeutics, Inc. 是一家致力于开发专有抗体类治疗药物的临床阶段生物制药公司[45] - CTX-009 是一种抗DLL4 x VEGF-A双特异性抗体，目前正在美国、韩国和中国的患有晚期实体瘤的患者中进行临床开发[46] - CTX-471 是一种CD137的单克隆抗体激动剂，已在小鼠模型中展现出对肿瘤微环境的显著影响[56] - CTX-8371 是一种同时靶向PD-1和PD-L1的双特异性抗体，已在小鼠模型中表现出优于PD-1、PD-L1或两者联合治疗的能力[65] - Compass Therapeutics 与 Merck & Co. 合作评估CTX-471与KEYTRUDA（pembrolizumab）的联合应用，旨在恢复患者对PD-1或PD-L1检查点抑制剂治疗的反应[62] 资金情况 - 截至2023年3月31日，Compass Therapeutics 通过出售股权证券融资主要资助了其运营，总共获得了4.09亿美元的募集资金[67] - 公司在2023年3月31日的三个月内运营亏损为7,837,000美元，较去年同期的7,162,000美元有所下降[76] - 公司在2023年3月31日的三个月内投资活动中获得了4,269,000美元的现金，主要来自于市场证券[85] - 公司截至2023年3月31日，现金、现金等价物和市场证券总额为175,000,000美元[80] - 公司预计未来的资金需求将主要用于研发支出，包括临床试验、产品制造和商业化等方面[81] - 公司相信目前的现金储备可以支持其运营支出和资本支出至2026年[88] 研发支出 - 研发支出主要包括与CTX-471、CTX-8371和CTX-009的开发相关的成本，如员工薪酬、与支持平台项目开发的组织的协议费用、合同制造组织的费用等[70] - 研发支出在2023年3月31日的三个月内增加了2,223,000美元，达到6,638,000美元，同比增长50%[76] - 总体而言，公司的研发支出主要用于CTX-009项目，该项目在2023年3月31日的三个月内花费了3,916,000美元[77] 内部控制 - 公司的管理层认为截至2023年3月31日，其披露控制和程序是有效的[90] - 公司在2023年第一季度没有发生对财务报告内部控制的重大变化[91]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-55939 Compass Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-4876496 (State or other jurisdict ...

Corporate Presentation December 2022 SRC DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes ava ...

Corporate Presentation November 2022 SRC DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes ava ...